What question did this study set out to answer?

To assess in vivo thrombin generation during long-term oral anticoagulant therapy by measuring plasma prothrombin fragment 1 + 2 (F1 + 2) levels.

June 1, 1993Blood Coagulation & Fibrinolysis

Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1 + 2

View Full Paper

Ask AI

Bookmark

Why the study?

Does long-term warfarin therapy reduce plasma levels of prothrombin fragment 1 + 2 in patients with thrombotic disease compared to healthy subjects?

Population

49 patients with thrombotic disease undergoing long-term warfarin therapy and 48 healthy subjects

Comparison

Long-term warfarin therapy vs Healthy subjects not receiving warfarin

Design

Cross-sectional

Authors

HTHiroyuki TakahashiKanagawa Prefectural Hospital Organization KWK. WadaNagoya Institute of Technology NSNaoki SatohJapan Aerospace Exploration Agency

Discussion

Member takes

Implication

Supports warfarin-mediated thrombin suppression at Thrombotest <30%; hypothesis-generating for F1+2-guided therapy.

Key Points

To assess in vivo thrombin generation during long-term oral anticoagulant therapy by measuring plasma prothrombin fragment 1 + 2 (F1 + 2) levels.
Measured plasma levels of F1 + 2, vitamin K–dependent clotting factors (II, VII, IX, X), and anticoagulant proteins C and S in 49 patients with thrombotic disease receiving long-term warfarin (Thrombotest ≤ 40%).
Compared patient biomarker concentrations against a reference group of 48 healthy subjects and stratified findings by Thrombotest intensity.
Mean plasma F1 + 2 concentrations were significantly lower in warfarin-treated patients than in 48 healthy controls, correlating positively with Thrombotest values and factors II, VII, IX, and X.
Patients with Thrombotest values under 30% exhibited a significant decrease in F1 + 2 levels compared to controls, whereas patients with values exceeding 30% maintained normal mean F1 + 2 levels.

Structured PICO

Does long-term warfarin therapy reduce plasma levels of prothrombin fragment 1 + 2 in patients with thrombotic disease compared to healthy subjects?

Population

49 patients with thrombotic disease undergoing long-term warfarin therapy (Thrombotest values ≤ 40%) and 48 healthy subjects

Intervention

Long-term warfarin therapy

Comparator

Healthy subjects not receiving warfarin

Outcome

Plasma levels of prothrombin fragment 1 + 2 (F1 + 2)surrogate

Long-term oral anticoagulant therapy suppresses thrombin generation in parallel to the decrease in coagulation factors, as indicated by decreased F1 + 2 levels.

Cite This Study

Takahashi et al. (1993) studied this question.

synapsesocial.com/papers/6a776434137c7dcc81bdcc6d https://doi.org/10.1097/00001721-199306000-00007

View Full Paper

Ask AI

Bookmark

Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1 + 2

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1 + 2

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider